OPILL
Clinical safety rating
cautionComprehensive clinical and safety monograph for OPILL (OPILL).
Combination oral contraceptive: progestin (norgestimate) suppresses gonadotropin release, inhibiting ovulation; estrogen (ethinyl estradiol) stabilizes endometrial lining and thickens cervical mucus, impeding sperm penetration.
| Metabolism | Ethinyl estradiol primarily metabolized by CYP3A4; norgestimate rapidly deacetylated to norgestrel and further metabolized by CYP3A4 and CYP2C9. |
| Excretion | Renal: ~50% (as unchanged drug and metabolites). Biliary/fecal: ~50% (as metabolites). |
| Half-life | Terminal half-life: 30-34 hours. Redistribution half-life: 2-4 hours. Clinical context: Steady state achieved in 5-7 days; dosing interval appropriate for once-daily administration. |
| Protein binding | ~99% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 4-6 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism). |
| Onset of Action | Oral: 30-60 minutes for therapeutic effect; peak plasma concentrations at 1-2 hours. |
| Duration of Action | Approximately 24 hours; clinical effect wanes over 12-24 hours post-dose. Once-daily dosing maintains sustained effect. |
| Molecular Weight | Ethinyl estradiol: 296.4 Da; Norgestimate: 369.5 Da |
1 tablet (norgestimate 0.180 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). For Child-Pugh class A or B, use only if benefits outweigh risks, with close monitoring. |
| Pediatric use | Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: 1 tablet daily for 21 days, then 7 days placebo. |
| Geriatric use | Not indicated for use in postmenopausal women. No studies in geriatric population; contraindicated in women >35 years who smoke cigarettes due to increased cardiovascular risk. |
| 1st trimester | Norgestimate/ethinyl estradiol combination oral contraceptive. Category X. Contraindicated in pregnancy. First trimester use associated with congenital defects (cardiac, limb reduction) in some studies, but data limited. Not indicated for use. |
| 2nd trimester | Category X. Contraindicated. No therapeutic indication in pregnancy. Accidental exposure unlikely to cause major malformations; fetal exposure if continued may cause androgenic effects? |
| 3rd trimester | Category X. Contraindicated. Late pregnancy use associated with fetal adrenal suppression and feminization of male fetuses? Avoid. |
Clinical note
Comprehensive clinical and safety monograph for OPILL (OPILL).
| Placental transfer | Placental transfer occurs; ethinyl estradiol crosses at ~2-5% of maternal serum level; norgestimate metabolites also cross. Transfer sufficient to exert hormonal effects on fetus. |
| Breastfeeding | Small amounts of ethinyl estradiol and norgestimate metabolites excreted in breast milk. May reduce milk production and quality. Not recommended in breastfeeding women, especially during the first 6 months postpartum. Alternative progestin-only methods preferred. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: Use is contraindicated due to risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Avoid use; potential for fetal androgenization of female fetuses and other adverse effects. |
| Fetal Monitoring | Monitor fetal development via ultrasound if inadvertent exposure occurs. Assess for signs of androgenization in female fetuses. No routine monitoring recommended as contraindicated in pregnancy. |
| Fertility Effects | Reversible inhibition of ovulation; normal fertility returns upon discontinuation. No long-term fertility impairment. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially >35 years). Women who use combination oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
Known or suspected pregnancyCurrent venous thromboembolism (VTE) or history of VTEMajor surgery with prolonged immobilizationCurrent or past arterial thromboembolic disease (e.g., MI, stroke)Active liver disease or hepatic impairmentBreast cancer (current or history)Estrogen-sensitive tumorsUndiagnosed abnormal uterine bleedingAge ≥35 and smoking ≥15 cigarettes per dayMigraine with aura if age ≥35Uncontrolled hypertension (≥160/100 mmHg)Diabetes with vascular diseaseHereditary thrombophilia
| Precautions | Increased risk of thromboembolic disorders (e.g., MI, stroke, VTE), Hepatic neoplasia risk, Elevated blood pressure, Gallbladder disease, Carbohydrate/lipid metabolic effects, Headache (including migraine), Uterine bleeding irregularities, Risk of pregnancy if missed pills |
| Food/Dietary | No specific food interactions have been reported with OPILL. Grapefruit juice does not affect norgestrel metabolism. However, taking the pill with food may reduce nausea if it occurs. |
| Clinical Pearls | OPILL is a progestin-only oral contraceptive containing norgestrel 0.075 mg. It must be taken at the same time daily; a delay of more than 3 hours requires backup contraception for 48 hours. Efficacy may be reduced with concurrent enzyme-inducing drugs (e.g., rifampin, certain anticonvulsants). Irregular bleeding is common and not a sign of reduced efficacy, but pregnancy should be ruled out if no withdrawal bleed occurs. OPILL does not increase thromboembolic risk and is safe for use in patients with contraindications to estrogen, including hypertension, migraine with aura, smoking >35 years, and history of thromboembolism. |
| Patient Advice | Take one pill at the same time every day without missing doses. · If you are more than 3 hours late taking a pill, use a backup birth control method (like condoms) for the next 48 hours. · OPILL does not protect against sexually transmitted infections; use condoms for STI prevention. · Irregular spotting or bleeding is common, especially in the first few months; do not stop taking the pill. · If you experience severe lower abdominal pain, heavy bleeding, or symptoms of ectopic pregnancy, seek medical attention immediately. · Tell your healthcare provider if you are taking any other medications, including over-the-counter drugs and herbal supplements. · If you vomit within 2 hours after taking a pill, take another pill as soon as possible and use backup contraception for 48 hours. |
Loading safety data…